STAAR Surgical Company (STAA) Stock: Price, Forecast & Analyst Target
STAAR Surgical Company (STAA) — MoonshotScore 80/100 (Exceptional band), calculated Nov 18, 2026. Price $24.22 (-3.24%), as of the Nov 20, 2026 trading session; market cap $1.22B.
Educational signal · not a buy or sell recommendation · How to read this
STAAR Surgical Company · STAA · NASDAQ
STAAR Surgical Company designs, develops, and markets implantable lenses for the eye. Their primary product, the Visian ICL, corrects vision disorders like myopia and astigmatism, offering an alternative to traditional refractive surgeries.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · STAAR Surgical Company (STAA)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, a strong balance sheet and elite growth, but a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Sound; Valuation: Full; Growth Durability: Compounding; Momentum: Rising.
- EPS beat 1 of the last 4 reports
- Altman Z 8.09 · Piotroski F 5
- ROE 0.1% · ROA 3.0% · current ratio 4.68
Helping: business quality, balance-sheet strength, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 63 | Fair | |
| 63 | Fair | |
| 63 | Fair | |
| 80 | Exceptional | |
| 80 | Exceptional | |
| 80 | Exceptional |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $24.22 | |
| Change on the day | -3.24% | |
| 52-week range | $15.59 – $35.87 | |
| Market capitalisation | $1.22B | — |
| Shares traded on the day | 585.6K |
Price & events
Other perspectives
Council score for STAAR Surgical Company (STAA): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
3 lenses, 3 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 19, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Two of these lenses read this company less favourably than the MoonshotScore does: Klarman-style lens and Moon AI lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Nov 19, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is STAAR Surgical Company (STAA), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. STAAR Surgical Company (STAA) is listed on NASDAQ. It employs 921 people and is led by Warren Foust. The market values it at $1.22B.
What do the latest results show for STAAR Surgical Company (STAA)?
Short answer · as of
Against analyst estimates the company has EPS beat 1 of the last 4 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $95M | $9M | $0.18 (diluted) |
| Dec 2025 | $58M | -$18M | -$0.37 (diluted) |
| Mar 2026 | $94M | $5M | $0.10 (diluted) |
| Jun 2026 | $94M | $8M | $0.16 (diluted) |
What are the financial strengths and risks for STAAR Surgical Company (STAA)?
Short answer
The MoonshotScore pillars rate business quality, balance-sheet strength, durable growth, positive momentum as strengths. The distress and quality screens read Altman Z 8.09 · Piotroski F 5. Trailing ratios: ROE 0.1% · ROA 3.0% · current ratio 4.68.
What should you watch next at STAAR Surgical Company (STAA)?
Short answer · as of
Analyst estimates on file carry FY2027 revenue $339.75M · EPS 0.35 · 7 analysts. Current published price targets run low $23.00 · high $34.00 · consensus $30.25 · median $32.00 against a quoted price of $24.22 (as of Nov 20, 2026).
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
Checked against the records this page reads, on the dates shown above.
How does STAAR Surgical Company compare with its peers?
Short answer
STAAR Surgical Company's score ranks 3rd of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $55.39 Nov 20, 2026 | $2.82B | 95 5-pillar Nov 18, 2026 | |
| $74.86 Nov 19, 2026 | $1.71B | 88 5-pillar Nov 18, 2026 | |
| STAAR Surgical Company (STAA) — this page | $24.22 | $1.22B | 80 |
| $15.65 Nov 20, 2026 | $4.27B | 73 5-pillar Nov 18, 2026 | |
| $172.52 Nov 20, 2026 | $4.31B | 73 5-pillar Nov 18, 2026 | |
| $44.80 Nov 20, 2026 | $1.87B | 64 5-pillar Nov 18, 2026 | |
| $23.12 Nov 20, 2026 | $2.87B | 62 5-pillar Nov 18, 2026 | |
| $3.38 Nov 20, 2026 | $538M | 41 5-pillar Nov 18, 2026 | |
| $32.67 Nov 19, 2026 | $300M | 39 5-pillar Nov 18, 2026 | |
| $10.81 Nov 20, 2026 | $455M | 37 5-pillar Nov 18, 2026 | |
| $8.29 Nov 20, 2026 | $1.65B | 31 5-pillar Nov 18, 2026 | |
| $44.41 Nov 19, 2026 | $3.27B | 27 5-pillar Nov 18, 2026 | |
| $10.71 Nov 20, 2026 | $1.25B | 26 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $23.00 – $34.00
- Consensus target
- $30.25
- Median target
- $32.00
- Revenue estimate
- $339.75M
- EPS estimate
- $0.35
Consensus record · Captured .
Measured against a quoted price of $24.22 (as of Nov 20, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Aug 14, 2026
- Transactions
- 48
- Identified insiders
- 10
- Purchases
- 0
- Sales
- 0
- Other transactions
- 48
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held STAA in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported STAA in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about STAAR Surgical Company (STAA)?
STAAR Surgical Company Stock: Key Questions Answered
These answers are editorial: 1 of these 9 answers is drawn from the STAA research dossier (written May 9, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for STAA?
STAA carries the MoonshotScore stated above — the Exceptional band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. STAAR Surgical Company designs, develops, and markets implantable lenses for the eye.
Is STAA a good stock to buy?
Stock Expert AI does not rate STAA buy, sell or hold. STAAR Surgical Company carries a MoonshotScore, in the Exceptional band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the STAA stock price today?
The last price recorded for STAAR Surgical Company (STAA), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the STAA price target?
The analyst consensus price target for STAAR Surgical Company (STAA), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What do analysts say about STAA stock?
Analyst coverage of STAAR Surgical Company (STAA) reflects a mixed outlook. While the company's innovative Visian ICL technology and strong gross margins are viewed positively, concerns remain regarding its profitability and competitive landscape.
What are the key factors to evaluate for STAA?
STAAR Surgical Company (STAA) holds a MoonshotScore in the high range. To weigh it, read the analyst view under Analyst targets & estimates on this page. No dividend is currently offered, indicating a focus on reinvesting earnings for growth. Not financial advice.
How frequently does STAA data refresh on this page?
STAA's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven STAA's recent stock price performance?
STAAR Surgical Company (STAA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary Visian ICL technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider STAA overvalued or undervalued right now?
STAAR Surgical Company (STAA) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 9, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 20 figures on this page — 10 from Financial Modeling Prep (FMP), 9 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com